亚洲在线日韩伦理片,96精品国产AⅤ一区二区,青鸟影视网,yy黄色频道,国内精品久久久精品AV电影院
Products
News
Resources
Contact
Language
簡體中文
繁體中文
English
日本語
???
Ti?ng Vi?t
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022
2022-03-15 09:00
Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea
2022-03-14 08:00
Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
2022-03-10 19:05
Everest Medicines Announces First Drug Approval of Trodelvy? in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer
2022-02-07 08:00
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide
2022-01-14 08:00
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy? in Combination with KEYTRUDA? (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
2022-01-10 21:35
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
2022-01-04 08:00
Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program
2021-12-20 20:55
Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO? (budesonide) to Reduce Proteinuria in IgA Nephropathy
2021-12-16 08:49
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
2021-12-15 08:00
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
2021-12-01 08:00
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index
2021-11-24 08:00
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index
2021-11-24 08:00
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
2021-11-11 08:05
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
2021-11-08 08:15
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
2021-11-08 08:10
Everest Medicines Announces Share Repurchase Transaction Details
2021-11-01 08:00
Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections
2021-09-29 17:44
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206
2021-09-24 13:56
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
2021-09-23 06:00